Chembio Diagnostics Inc  

(Public, NASDAQ:CEMI)   Watch this stock  
Find more results for CEMI
-0.01 (-0.20%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.95 - 5.16
52 week 3.33 - 5.53
Open 5.16
Vol / Avg. 3,500.00/18,041.00
Mkt cap 48.44M
P/E     -
Div/yield     -
EPS -0.23
Shares 9.63M
Beta 0.97
Inst. own 17%
Mar 3, 2016
Q4 2015 Chembio Diagnostics Inc Earnings Release (Estimated) Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -6.35% -4.11%
Operating margin -8.41% -5.61%
EBITD margin - -2.93%
Return on average assets -7.57% -4.60%
Return on average equity -9.52% -5.70%
Employees 166 -
CDP Score - -


3661 Horseblock Rd
MEDFORD, NY 11763-2215
United States - Map
+1-631-9241135 (Phone)
+1-775-8849383 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Chembio Diagnostics, Inc. (Chembio), and its wholly owned subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's main products presently commercially available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format, and a barrel format. Its Dual Path Platform (DPP) HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. Additionally, Chembio's product pipeline includes a multiplex test that detects P24 HIV antigen, as well as HIV 1/2 antibodies, and a rapid test for the detection of Hepatitis-C antibodies.

Officers and directors

John J. Sperzel III President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Richard J. Larkin Chief Financial Officer
Age: 58
Bio & Compensation  - Reuters
Sharon Klugewicz Chief Operating Officer
Age: 47
Bio & Compensation  - Reuters
Javan Esfandiari Executive Vice President - Research and Development
Age: 48
Bio & Compensation  - Reuters
Tom Ippolito Vice President - Regulatory Affairs, Quality Assurance and Quality Control
Age: 52
Bio & Compensation  - Reuters
Paul Lambotte Ph.D. Vice President - Product Development
Age: 63
Bio & Compensation  - Reuters
Michael K. Steele Vice President - Business Development, Sales and Marketing
Age: 48
Bio & Compensation  - Reuters
Katherine L. Davis Non-Executive Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Barbara A. DeBuono M.D., M.P.H. Independent Director
Age: 59
Bio & Compensation  - Reuters
Peter T. Kissinger Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters